Exenatide modulates tumor–endothelial cell interactions in human ovarian cancer cells
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Diabetes and cancer are prevalent diseases whose incidence is increasing globally. Diabetic women have a moderate risk increase in ovarian cancer, suggested to be due to an interaction between these two disorders. Furthermore, patients manifesting both diseases have associated worse prognosis, reduced survival and shorter relapse-free survival. According to current recommendations, incretin drugs such as Exenatide, a synthetic analog of Exendin-4, and Liraglutide are used as therapy for the type 2 diabetes (T2D). We studied the effects of GLP-1 and Exendin-4 on migration, apoptosis and metalloproteinase production in two human ovarian cancer cells (SKOV-3 and CAOV-3). Exendin-4 inhibited migration and promoted apoptosis through caspase 3/7 activation. Exendin-4 also modulated the expression of key metalloproteinases (MMP-2 and MMP-9) and their inhibitors (TIMP-1 and TIMP-2). Vascular endothelial cells, which contribute to the formation and progression of metastasis, were also analyzed. TNF-α-stimulated endothelial cells from iliac artery after Exendin-4 treatment showed reduced production of adhesion molecules (ICAM-1 and VCAM-1). Additionally, incretin treatment inhibited activation of apoptosis in TNF-α-stimulated endothelial cells. In the same experiment, MMPs (MMP-1 and MMP-9), which are relevant for tumor development, were also reduced. Our study demonstrated that incretin drugs may reduce cancer cell proliferation and dissemination potential, hence limiting the risk of metastasis in epithelial ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
Balkwill, F., Charles, K. A., & Mantovani, A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.013 · Cited by 1,769
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806
Tumor necrosis factor and cancer, buddies or foes?
Wang, X., & Lin, Y. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00889.x · Cited by 730
Initiation and execution mechanisms of necroptosis: an overview
Grootjans, S., Vanden Berghe, T., & Vandenabeele, P. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.65 · Cited by 566
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
Alves, C., Batel-Marques, F., & Macedo, A. F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.008 · Cited by 186
on behalf of the Diabetes and Cancer Research Consortium, Carstensen, B., Read, S. H., Friis, S., Sund, R., Keskimäki, I., Svensson, A.-M., Ljung, R., Wild, S. H., Kerssens, J. J., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3884-9 · Cited by 180
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Juurlink, D. N., Targownik, L. E., Turin, T. C., et al. (2016) · BMJ · doi:10.1136/bmj.i581 · Cited by 120
Glucagon-Like-Peptide-1 Receptor Expression in Normal and Diseased Human Thyroid and Pancreas
Waser, B., Blank, A., Karamitopoulou, E., Perren, A., & Reubi, J. C. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.113 · Cited by 119
Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells
He, W., Yu, S., Wang, L., He, M., Cao, X., Li, Y., & Xiao, H. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.07.032 · Cited by 58
Garczorz, W., Francuz, T., Siemianowicz, K., Kosowska, A., Kłych, A., Aghdam, M. R. F., & Jagoda, K. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.08.007 · Cited by 12
Self-citation
Cited by
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer
Cani, P. D., & Jordan, B. F. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0025-6 · Cited by 383
Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists
Kelly, C. A., & Sipos, J. A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae722 · Cited by 30
Kim, M., Kim, S. C., Kim, J., & Kim, B. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0105 · Cited by 26
“Contrasting with concerns about pancreatic and thyroid cancers, emerging evidence suggests that GLP-1 RAs may inhibit the growth of several types of cancer, including ovarian, breast, cervical, prostate, and pancreatic cancers [29-31].”
Metadata
- Authors
- Kosowska, A., Gallego-Colon, E., Garczorz, W., Kłych-Ratuszny, A., Aghdam, M. R. F., Woz´niak, M., Witek, A., Wróblewska-Czech, A., Cygal, A., Wojnar, J., & Francuz, T.
- Venue
- Endocrine Connections
- Publisher
- Bioscientifica
- Published
- 2017-11
- Volume
- 6
- Issue
- 8
- Pages
- 856-865
- ISSN
- 2049-3614 (ISSN-L)
- OpenAlex
- W2765114354
- Cited by
- 45
- References
- 12
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.